BSIM Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$575K
- Investors
-
6
BSIM Therapeutics General Information
Description
Operator of a biotechnology company intended to fight neurodegenerative amyloid diseases. The company focuses on the design of organ-targeted, quality drug candidates for the treatment of transthyretin-mediated amyloidosis, enabling patients to improve their lives through innovative therapeutic approaches.
Contact Information
Website
www.bsimtx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- Instituto Pedro Nunes
- Rua Pedro Nunes, Edifício C, Sala 2.15
- Coimbra, 3030-199
- Portugal
+351 239 000 000
BSIM Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 15-Feb-2020 | $575K | 000 | Completed | Generating Revenue | |
| 5. Later Stage VC | 01-Aug-2019 | 00000 | 000 | 00.000 | Completed | Generating Revenue |
| 4. Accelerator/Incubator | 00000 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 10-Jun-2019 | 00000 | Completed | Generating Revenue | ||
| 2. Seed Round | 23-Jun-2017 | $616K | $616K | 00.000 | Completed | Generating Revenue |
| 1. Accelerator/Incubator | Completed | Startup |
BSIM Therapeutics Patents
BSIM Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4029859-A1 | 2-oxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | Pending | 21-Nov-2014 | 0000000000 | 0 |
| US-20220041566-A1 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | Active | 21-Nov-2014 | 0000000000 | |
| US-11584727-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | Active | 21-Nov-2014 | 0000000000 | 00 |
| US-11117877-B2 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | Active | 21-Nov-2014 | 0000000000 | |
| EP-3221299-A1 | 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof | Pending | 21-Nov-2014 | C07D277/36 |
BSIM Therapeutics Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Rui Brito Ph.D | Co-Founder, Chief Executive Officer & Board Member | ||
| Carlos Simoes Ph.D | Co-Founder, Chief Technology Officer & Board Member |
BSIM Therapeutics Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carlos Simoes Ph.D | BSIM Therapeutics | Co-Founder, Chief Technology Officer & Board Member | 000 0000 |
| Eric Leire MD | Self | Board Member | 000 0000 |
| Raúl Saraiva Ph.D | Portugal Ventures | Board Member | 000 0000 |
| Rui Brito Ph.D | BSIM Therapeutics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
BSIM Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BSIM Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Portugal 2020 | Government | 000 0000 | 000000 0 | ||
| Bluepharma | Corporation | Minority | 000 0000 | 000000 0 | |
| a2b SGPS | Angel Group | Minority | 000 0000 | 000000 0 | |
| Portugal Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Building Global Innovators | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |